Startpage - Formycon AG

1-StartSlider_600x1920

Commercial Stage
Biosimilar Developer

As a globally operating, independent biosimilar developer, Formycon actively contributes to improving patients' access to high-quality, safe and affordable biologic medicines.

LEARN MORE

Latest News

Corporate News

Formycon’s FYB201/Ranivisio® sets innovative standard as Europe’s First Ranibizumab Biosimilar available in Pre-filled Syringe

October 21, 2025

Corporate News

Actor Pharmaceuticals and Megalabs become partners for the commercialization of Formycon’s Eylea® biosimilar FYB203 (aflibercept) for Australia and Latin America

October 16, 2025

Corporate News

Formycon secures U.S. License Date for proposed Aflibercept Biosimilar FYB203 following settlement and license agreement with Regeneron

October 2, 2025

Key financial figures

Biosimilars

Biosimilar Candidates

Portfolio

Projekt

Technische
Entwicklung

Herstellung

Klinische
Entwicklung

Zulassung

Vermarktung

FYB201

FYB202

FYB203

FYB206

FYB208

FYB209

FYB210

Latest News

Formycon’s FYB201/Ranivisio® sets innovative standard as Europe’s First Ranibizumab Biosimilar available in Pre-filled Syringe

Actor Pharmaceuticals and Megalabs become partners for the commercialization of Formycon’s Eylea® biosimilar FYB203 (aflibercept) for Australia and Latin America

Formycon secures U.S. License Date for proposed Aflibercept Biosimilar FYB203 following settlement and license agreement with Regeneron

Key financial figures

Biosimilars

Biosimilar Candidates

Portfolio

#TeamFormycon